Shankar-Hari Group

Manu Shankar-Hari leads this translational research group.  

Shankar-Hari group’s research explores ways to improve outcomes in adult critically ill patients with sepsis and with ARDS, by linking the illness immunobiology with novel interventional trial designs.

Our lab has the following focussed research themes

1. Immunobiology: Explore adaptive immune system changes during sepsis, during ARDS and longer-term in patients who survive sepsis. We integrate orthogonal multilevel data with repeated measurements of cellular phenotype, functional assessments, alongside corresponding transcriptomes and epigenetic landscapes.
2. Epidemiology and Stratified medicine: We use early-phase randomised controlled trials, cohort studies, systematic reviews and large clinical trial datasets to  (a) explore treatment effect heterogeneity; (b) identify treatable traits based on dominant biological mechanisms, and (c) modifiable proximate determinants of sepsis and ARDS.
3. COVID-19 research focuses on clinical trials, translational immunology and children with PIMS-TS illness: Translational immunology in adults focuses on how the immune system responses are influenced by treatment with convalescent plasma and recombinant interleukin-7 in the respective clinical trials.

Current PhD students

Rohit Saha

Matthew Fish

Aislinn Jennings

Julie Wilson